Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ACB Stock Forecast 2025-2026
$4.68
Current Price
$256.86M
Market Cap
Buy 3
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to ACB Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
ACB Price Momentum
-20.0%
1 Week Change
-12.4%
1 Month Change
-15.2%
1 Year Change
+10.1%
Year-to-Date Change
-35.0%
From 52W High of $7.20
+36.0%
From 52W Low of $3.44
📊 TOP ANALYST CALLS
Did ACB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aurora Cannabis is one of their latest high-conviction picks.
Latest ACB Stock Price Targets & Analyst Predictions
ACB has shown a year-to-date change of 10.1% and a 1-year change of -15.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for ACB. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACB Analyst Ratings
3
Buy
2
Hold
0
Sell
ACB Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $4.68
Latest ACB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 27, 2024 | Zuanic & Associates | Pablo Zuanic | Neutral | Initiates | $0.00 |
| Jun 16, 2023 | CIBC | John Zamparo | Neutral | Maintains | $1.00 |
| Jun 15, 2023 | Canaccord Genuity | Matt Bottomley | Hold | Maintains | $0.80 |
| Feb 13, 2023 | CIBC | John Zamparo | Neutral | Maintains | $1.75 |
| Sep 21, 2022 | Piper Sandler | Michael Lavery | Neutral | Maintains | $3.00 |
| Sep 28, 2021 | MKM Partners | Bill Kirk | Neutral | Upgrade | $0.00 |
| Dec 18, 2020 | BMO Capital | Tamy Chen | Underperform | Downgrade | $9.00 |
| Nov 25, 2020 | Cowen & Co. | Outperform | Initiates | $0.00 | |
| Nov 25, 2020 | Desjardins | Buy | Initiates | $0.00 | |
| Nov 25, 2020 | Piper Sandler | Neutral | Maintains | $0.00 | |
| Nov 25, 2020 | Jefferies | Buy | Initiates | $0.00 | |
| Nov 25, 2020 | Needham | Hold | Initiates | $0.00 | |
| Nov 25, 2020 | Piper Jaffray | Neutral | Maintains | $0.00 | |
| Nov 25, 2020 | Bank of America | Neutral | Downgrade | $0.00 | |
| Nov 25, 2020 | Stifel Nicolaus | Hold | Initiates | $0.00 | |
| Nov 25, 2020 | Stifel | Sell | Downgrade | $0.00 | |
| Nov 25, 2020 | B of A Securities | Neutral | Downgrade | $0.00 | |
| Nov 25, 2020 | Seaport Global | Neutral | Initiates | $0.00 | |
| Nov 25, 2020 | Ladenburg Thalmann | Neutral | Downgrade | $0.00 | |
| Nov 25, 2020 | MKM Partners | Sell | Initiates | $0.00 |
Aurora Cannabis Inc. (ACB) Competitors
The following stocks are similar to Aurora Cannabis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ACB
Aurora Cannabis
mkt cap
321.07M
Aurora Cannabis Inc. (ACB) Financial Data
Aurora Cannabis Inc. has a market capitalization of $256.86M with a P/E ratio of 21.3x. The company generates $250.68M in trailing twelve-month revenue with a 0.7% profit margin.
Revenue growth is +34.3% quarter-over-quarter, while maintaining an operating margin of -32.9% and return on equity of +2.6%.
Valuation Metrics
Market Cap
$256.86M
Enterprise Value
$193.75M
P/E Ratio
21.3x
PEG Ratio
-42.5x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
+34.3%
Gross Margin
+24.2%
Operating Margin
-32.9%
Net Margin
+0.7%
EPS Growth
+34.3%
Financial Health
Cash/Price Ratio
+53.7%
Current Ratio
4.3x
Debt/Equity
17.2x
ROE
+2.6%
ROA
+0.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aurora Cannabis Inc. (ACB) Business Model
About Aurora Cannabis Inc.
What They Do
Produces medicinal and recreational cannabis products.
Business Model
Aurora Cannabis operates a vast network of production facilities, generating revenue through the sale of high-quality cannabis products for both medical and adult-use markets. The company leverages scientific innovation and cultivation expertise to create diverse offerings, which are distributed through extensive domestic and international channels.
Additional Information
Headquartered in Edmonton, Canada, Aurora is recognized for its significant impact on healthcare by providing solutions for chronic pain and mental health disorders. The company also emphasizes advancements in cultivation technology, maintaining a strong position in the competitive global cannabis industry.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,073
CEO
Mr. Miguel Martin
Country
Canada
IPO Year
2014
Website
www.auroramj.comAurora Cannabis Inc. (ACB) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Aurora Cannabis Inc. (ACB) Misses Q4 Earnings Estimates
Aurora Cannabis (ACB) delivered earnings and revenue surprises of -36.36% and 1.65%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Jun 18, 2025
By Zacks Equity Research
Tale of the Tape
High Tide Inc. (HITI) Reports Q2 Loss, Tops Revenue Estimates
High Tide (HITI) delivered earnings and revenue surprises of -50% and 0.22%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?
Jun 16, 2025
By Zacks Equity Research
Tale of the Tape
Cannabis Stock CGC Rallies 39% in Three Months: Time to Buy or Sell?
Canopy Growth surges 39% in three months as restructuring, margin gains and debt cuts renew investor interest.
Jun 13, 2025
By Sundeep Ganoria
Analyst Blog
Latest News
Quick Summary
Aurora Cannabis reported a narrowed loss in Q4 fiscal results, attributed to strong growth in its medical-cannabis sector.
Why It Matters
Aurora Cannabis's reduced losses and growth in its medical-cannabis sector indicate improving operational efficiency and potential for future profitability, enhancing investor confidence.
Source: Market Watch
Market Sentiment:
Positive
Quick Summary
Aurora Cannabis (ACB) shares fell as the company anticipates "temporary declines" in its international markets, including the U.S.
Why It Matters
Aurora Cannabis' expected declines in international markets, including the U.S., signal potential revenue challenges, affecting investor confidence and share performance.
Source: Investopedia
Market Sentiment:
Negative
Canadian Medical Marijuana Firm Aurora Cannabis Expects Weak Demand In International Market
2 days ago
Quick Summary
Aurora Cannabis Inc. (ACB) stock is down following the release of its fourth quarter 2025 earnings report.
Why It Matters
Aurora Cannabis Inc.'s lower stock price following its Q4 2025 earnings indicates potential financial struggles, affecting investor confidence and future market performance.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Aurora Cannabis reported a decline due to regulatory issues in Poland affecting prescription volumes and increased logistics costs impacting margins in Q4.
Why It Matters
Aurora Cannabis' drop indicates regulatory challenges impacting sales and increased costs affecting profitability, signaling potential risks to future earnings and investor sentiment.
Source: Market Watch
Market Sentiment:
Negative
Quick Summary
Aurora Cannabis reported mixed Q4/FY2025 results: higher revenues but lower profitability due to one-time expenses. Medical cannabis sales were flat, with expected declines in Q1/FY2026 due to regulatory changes.
Why It Matters
Mixed results from Aurora Cannabis indicate potential volatility ahead, with flat medical sales and regulatory headwinds likely impacting future profitability and growth prospects.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
Aurora Cannabis Inc. (ACB) reported record annual medical cannabis net revenue of $244.4 million, a 39% increase YOY. Adjusted EBITDA rose 261% to $49.7 million, with $9.9 million in positive free cash flow.
Why It Matters
Aurora Cannabis’ record revenue and EBITDA growth signal strong operational performance, enhancing its attractiveness to investors seeking growth in the medical cannabis sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ACB Stock
What is Aurora Cannabis Inc.'s (ACB) stock forecast for 2025?
Analyst forecasts for Aurora Cannabis Inc. (ACB) are not currently available. The stock is trading at $4.68.
Is ACB stock a good investment in 2025?
According to current analyst ratings, ACB has 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.68. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACB stock?
Price predictions from Wall Street analysts for ACB are not currently available. The stock is trading at $4.68.
What is Aurora Cannabis Inc.'s business model?
Aurora Cannabis operates a vast network of production facilities, generating revenue through the sale of high-quality cannabis products for both medical and adult-use markets. The company leverages scientific innovation and cultivation expertise to create diverse offerings, which are distributed through extensive domestic and international channels.
What is the highest forecasted price for ACB Aurora Cannabis Inc.?
Price targets from Wall Street analysts for ACB are not currently available. The stock is trading at $4.68.
What is the lowest forecasted price for ACB Aurora Cannabis Inc.?
Price targets from Wall Street analysts for ACB are not currently available. The stock is trading at $4.68.
What is the overall ACB consensus from analysts for Aurora Cannabis Inc.?
The overall analyst consensus for ACB is bullish. Out of 7 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 0 as Sell.
How accurate are ACB stock price projections?
Stock price projections, including those for Aurora Cannabis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 20, 2025 2:39 PM UTC